Suppr超能文献

接受淋巴细胞免疫疗法治疗的复发性流产夫妇的妊娠及围产期结局

Gestational and perinatal outcomes in recurrent miscarriages couples treated with lymphocyte immunotherapy.

作者信息

Sarno Manoel, Cavalcante Marcelo Borges, Niag Marla, Pimentel Kleber, Luz Ivana, Figueiredo Bianca, Michelon Tatiana, Neumann Jorge, Lima Simone, Machado Isabela Nelly, Araujo Júnior Edward, Barini Ricardo

机构信息

Department of Obstetrics and Gynecology, Federal University of Bahia (UFBA), Salvador, BA, Brazil.

Department of Obstetrics and Gynecology, Fortaleza University (UNIFOR), Fortaleza, CE, Brazil.

出版信息

Eur J Obstet Gynecol Reprod Biol X. 2019 May 7;3:100036. doi: 10.1016/j.eurox.2019.100036. eCollection 2019 Jul.

Abstract

OBJECTIVE

This study aims to elucidate which types of recurrent miscarriage (RM) patients experienced a livebirth after paternal lymphocyte immunotherapy (LIT) and to evaluate the perinatal outcome.

STUDY DESIGN

Retrospective analysis of a multicenter, observational study which enrolled 1096 couples with a history of two or more spontaneous miscarriages without any intercalated delivery. We conducted an intention-to-treat analysis of couples with RM treated with or without LIT regarding to gestational and perinatal outcomes. We compared groups by using the Student's -test or Kruskal-Wallis test, Fisher's exac-test and test when appropriate.

RESULTS

The success of gestation was significantly higher in the LIT group (60.1% vs. 33.1%;  <  0.001). A sub-analysis of four different immune disorder groups revealed a significantly higher success in the LIT group in all immune categories, except in patients who had autoantibodies positive. We observed no significant differences in perinatal outcomes such as gestational age at birth, preterm and extreme preterm birth, and birth weight in successful pregnancy in both groups. The success rate was significantly higher when LIT was administrated before and during pregnancy and only during pregnancy compared to only before pregnancy ( <  0.01).

CONCLUSIONS

Careful laboratory test phenotyping of RM patients may identify subgroups most likely to benefit and exclude those with little likelihood of benefit, and LIT during a pregnancy may significantly improve success rates.

摘要

目的

本研究旨在阐明哪些类型的复发性流产(RM)患者在接受父淋巴细胞免疫疗法(LIT)后成功分娩,并评估围产期结局。

研究设计

对一项多中心观察性研究进行回顾性分析,该研究纳入了1096对有两次或更多次自然流产史且无中间分娩的夫妇。我们对接受或未接受LIT治疗的RM夫妇的妊娠和围产期结局进行了意向性分析。我们在适当的时候使用学生t检验或Kruskal-Wallis检验、Fisher精确检验和卡方检验对各组进行比较。

结果

LIT组的妊娠成功率显著更高(60.1%对33.1%;P<0.001)。对四个不同免疫紊乱组的亚分析显示,除自身抗体阳性的患者外,LIT组在所有免疫类别中的成功率均显著更高。我们观察到两组成功妊娠的围产期结局,如出生时的孕周、早产和极早产以及出生体重,均无显著差异。与仅在妊娠前相比,在妊娠前和妊娠期间以及仅在妊娠期间进行LIT时,成功率显著更高(P<0.01)。

结论

对RM患者进行仔细的实验室测试表型分析可能会识别出最有可能受益的亚组,并排除受益可能性较小的亚组,并且在妊娠期间进行LIT可能会显著提高成功率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9638/6687386/7786c06773d7/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验